Substituted oxazole benzenesulfonamides as potent human β3 adrenergic receptor agonists
摘要:
As a part of our investigation into the development of orally bioavailable beta(3) adrenergic receptor agonists, we have identified a series of substituted oxazole derivatives that are potent beta(3) agonists with excellent selectivity against other beta receptors. Several of these compounds showed excellent oral bioavailability in dogs. One example, cyclopentylethyloxazole 5f is a potent beta(3) agonist (EC50 = 14 nM, 84% activation) with 340-fold and 160-fold selectivity over beta(1) and beta(2) receptors, respectively, and has 38% oral bioavailability in dogs. (C) 2000 Elsevier Science Ltd. All rights reserved.
Substituted oxazole benzenesulfonamides as potent human β3 adrenergic receptor agonists
摘要:
As a part of our investigation into the development of orally bioavailable beta(3) adrenergic receptor agonists, we have identified a series of substituted oxazole derivatives that are potent beta(3) agonists with excellent selectivity against other beta receptors. Several of these compounds showed excellent oral bioavailability in dogs. One example, cyclopentylethyloxazole 5f is a potent beta(3) agonist (EC50 = 14 nM, 84% activation) with 340-fold and 160-fold selectivity over beta(1) and beta(2) receptors, respectively, and has 38% oral bioavailability in dogs. (C) 2000 Elsevier Science Ltd. All rights reserved.
Long‐ing alkyl chain: The catalytic direct CH alkylation of azoles with unactivatedalkyl bromides and chlorides is described. A palladium catalyst enables the alkylation of oxazoles, whereas a nickel one shows unique activity for thiazole. The catalyses allow a straightforward access to azole motifs bearing long, functional alkyl side chains.